Effect of Insulin Detemir on Blood Glucose Control in Subjects With Type 2 Diabetes
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
This trial is conducted in China. This trial aims for a comparison of the effect on glycemic control in subjects with type 2 diabetes of insulin detemir or NPH-insulin given once daily at bedtime as add-on to oral anti-diabetic drug(s).
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Type 2 diabetes
HbA1C greater than 7.5% and less than or equal to 11.0%
Currently on any oral antidiabetic drug (OAD) more than or equal to 3 months
Previous acute treatment with insulin for more than 7 days.
Treatment with OAD(s) which does not adhere to the approval labeling.
Proliferate retinopathy or maculopathy that has required acute treatment within the last year.
Known hypoglycaemia unawareness or recurrent major hypoglycaemia, that may interfere with study participation as judged by the Investigator.